Drug Discovery & Development

NCI Experimental Therapeutics (NExT) Program

NCI’s Experimental Therapeutics (NExT) program shortens the timeline for new drug development and advances breakthroughs into new cancer therapies. For example, through the NExT program, promising molecules such as the angiogenesis inhibitor cediranib and olaparib, which inhibits the repair of DNA damage, are being tested as a combination treatment for ovarian cancer and mesothelioma. The NExT Program is also supporting another promising therapeutic (selumetinib) to treat childhood brain tumors.